Reuters: Regulatory News: UPDATE 1-OncoMed Pharma files for IPO of up to $115 mln

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-OncoMed Pharma files for IPO of up to $115 mln May 11th 2012, 16:21 Fri May 11, 2012 12:21pm EDT May 11 (Reuters) - Cancer drug maker OncoMed Pharmaceuticals Inc filed with U.S. regulators on Friday to raise up to $115 million in an initial public offering of common stock. The company told the U.S. Securities and Exchange Commission in a preliminary prospectus that Jefferies, Leerink Swann, Piper Jaffray and BMO Capital Markets were underwriting the IPO. OncoMed, which focuses on developing antibody therapeutics targeting cancer stem cells, said that it has strategic alliances in place with GlaxoSmithKline and Bayer . The filing did not reveal how many shares the company planned to sell or their expected price. Entities affiliated with GlaxoSmithKline LLC hold an 11.74 percent stake in OncoMed before the offering. The amount of money a company says it plans to raise in its first IPO filings is used to calculate registration fees. The final size of the IPO could be different.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions